Research progress of myeloproliferative disorders: several clinical problems post the JAK2 mutation era

VernacularTitle:骨髓增殖性疾病的研究进展:后JAK2突变时代的几个临床问题
Author: Ding TIAN ; Ping ZHU ; Jianliang SHEN ; Zhao WANG
Publication Type:Journal Article
Keywords: Myeloproliferation disorders; Gene,JAK2; Mutation; Diagnosis; Therapy
From: Journal of Leukemia & Lymphoma 2010;19(1):4-7
CountryChina
Language:Chinese
Abstract: This critical review was summarized more systematically about the JAK2V617F mutation of related research progress in myeloproliferative disorders (MPD) research fields and the identification of JAK2V617F mutation represents an important advance in our understanding of MPD was agreed. The authors focused on several sensitive problems of post the JAK2 mutation era, and expressed their opinions. The Guideline of the MPD diagnostic criteria recommended by WHO in 2008 was accepted. The authors recommend the MPD, rather than myeloproliferative neoplasm (MPN). The treatment for the MPD (not including the CML) is recommended. Before the effective targeting of JAK2V617F specific inhibitors for the treatment of the MPD, short-term of use hydroxyurea (HU) was suggested to suppress excessive proliferation of bone marrow of MPD and a long course of treatment application of inteferon-α(IFN-α), and low-dose of aspirin in a timely manner were recommended to prevent thrombosis and other complications.